Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX · NASDAQ Global Select
+$0.04 today
Vol 22.41M · Avg 15.60M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:RXRX · Revenue to Net Income
Key Ratios
Analysis
$66.3M of revenue converted into -$559.8M of net income for the selected period. Gross margin is -136.5% and net margin is -1538.7%, showing how much revenue survives after costs and taxes. EPS is $-1.20, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.7M +26.9% | $58.8M +34.1% | $43.9M +10.6% | $39.7M +296.8% | $10.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $121.0M +167.4% | $45.2M +6.2% | $42.6M -11.8% | $48.3M | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$46.3M -440.2% | $13.6M +955.2% | $1.3M +115.0% | -$8.6M -185.9% | $10.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | -62.0% -85.1pp | 23.1% +20.2pp | 2.9% +24.6pp | -21.7% -121.7pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $425.3M +35.3% | $314.4M +30.3% | $241.2M +54.9% | $155.7M +15.1% | $135.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $176.6M -0.9% | $178.2M +60.8% | $110.8M +35.8% | $81.6M +41.5% | $57.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $601.9M +22.2% | $492.6M +40.2% | $351.3M +48.2% | $237.1M +23.0% | $192.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $83.7M +129.4% | $36.5M +49.6% | $24.4M +107.6% | $11.8M +39.9% | $8.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$559.4M -31.1% | -$426.7M -38.7% | -$307.6M -35.1% | -$227.7M -30.0% | -$175.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -749.0% -23.8pp | -725.2% -24.1pp | -701.1% -127.4pp | -573.7% +1177.5pp | -1751.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$648.1M -35.3% | -$479.0M -36.8% | -$350.1M -42.5% | -$245.7M -34.4% | -$182.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -867.9% -53.8pp | -814.1% -16.3pp | -797.8% -178.6pp | -619.3% +1208.5pp | -1827.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $22.8M +44.6% | $15.8M -17.6% | $19.1M +205.7% | $6.3M +8467.1% | $73.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.8M +15.1% | $1.6M +1520.6% | $97.0K +76.4% | $55.0K -98.1% | $3.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $3.2M -77.2% | $14.2M -20.7% | $17.9M +186.9% | $6.3M +268.8% | -$3.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$644.9M -38.8% | -$464.8M -39.9% | -$332.1M -38.7% | -$239.5M -28.4% | -$186.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -863.5% -73.6pp | -789.9% -33.0pp | -757.0% -153.5pp | -603.5% +1261.3pp | -1864.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$136.0K +87.9% | -$1.1M +72.3% | -$4.1M | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$644.8M -39.1% | -$463.7M -41.3% | -$328.1M -37.0% | -$239.5M -28.4% | -$186.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -863.4% -75.3pp | -788.0% -40.3pp | -747.7% -144.2pp | -603.5% +1261.3pp | -1864.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +14.8% | -$2 -7.0% | -$2 -16.2% | -$1 -29.5% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +14.8% | -$2 -7.0% | -$2 -16.2% | -$1 -29.5% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $447.4M +63.2% | $274.2M +31.9% | $207.9M +18.4% | $175.5M +3.1% | $170.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $447.4M +63.2% | $274.2M +31.9% | $207.9M +18.4% | $175.5M +3.1% | $170.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.41B
Liquidia Corporation
NASDAQ:LQDA
$6.02B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.80B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.70B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.36B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.99B
Galapagos N.V.
GLPG
$1.84B
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
$1.82B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RXRX generate?
Recursion Pharmaceuticals, Inc. (RXRX) reported $74.68M of revenue in fiscal 2025.
Is RXRX profitable?
Recursion Pharmaceuticals, Inc. (RXRX) reported -$644,759,000.00 of net income, with a net margin of -863.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.